Compare AstraZeneca plc (AZN) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Waste Management, Inc. — how do they compare? AstraZeneca plc trades at $157.95 (market cap $248.14B), while Waste Management, Inc. trades at $228.22 (market cap $90.68B). The key difference: AstraZeneca plc is far larger — about 2.7× Waste Management, Inc.'s market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | WM | |
|---|---|---|
Market Cap | $248.14B | $90.68B |
Sector | Health | Industrials |
52-Week High | $209.48 | $246.51 |
52-Week Low | $147.06 | $196.77 |
Enterprise Value | $275.41B | $113.47B |
Dividend Yield | 2.01% | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
WM trades at $226.6, down 0.47% over 24 hours, with a bullish technical signal and support near $226. The stock shows strong profitability with a 40.6% gross margin and 11.12% net margin, though its P/E of 59.74 is elevated. Recent Q2 2026 earnings beat expectations at $2.02 per share, and analyst consensus is a buy with a $263.43 price target. Cash flow from operations grew to $6.04B in 2025, but net cash flow was negative $190M due to investments.
Outlook is positive with revenue growth and margin stability, but risks include high valuation and debt levels. The stock offers upside to the consensus target, supported by institutional confidence and consistent earnings beats, though investors should monitor volume trends and interest rate impacts on borrowing costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
